ANI Pharmaceuticals
ANIP
132 hedge funds and large institutions have $413M invested in ANI Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
73% more capital invested
Capital invested by funds: $239M → $413M (+$175M)
67% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 30
13% more funds holding
Funds holding: 117 → 132 (+15)
3.5% less ownership
Funds ownership: 57.11% → 53.6% (-3.5%)
36% less call options, than puts
Call options by funds: $2.3M | Put options by funds: $3.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$13.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.9M |
| 3 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$9.47M |
| 4 |
BlackRock
New York
|
+$7.52M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$11.7M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$7.35M |
| 3 |
Morgan Stanley
New York
|
-$2.32M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$1.09M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.08M |
ANIP Hedge Fund Activity: Q4 2021 in Review
132 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2021, worth a combined $413M — up 73% from $239M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ANIP positions and 19 closed out — a net gain of 16 holders — while 50 added to existing stakes and 30 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $13.2M. The largest seller was Goldman Sachs, cutting an estimated $11.7M.
- 132 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2021, up from 117 in Q3 2021.
- Funds reported $413M of ANI Pharmaceuticals stock for Q4 2021, up 73% quarter-over-quarter.
- 35 funds opened new ANI Pharmaceuticals positions in Q4 2021 and 19 closed out, a net change of +16 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2021 was Rubric Capital Management (New York), an estimated $13.2M added.
- The largest ANI Pharmaceuticals seller in Q4 2021 was Goldman Sachs, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2021.